To ascertain if the VAF347 therapeutic regimen was sufficient to ameliorate diabetes-mediated Th17 cell differentiation, spleens were collected from non-diabetic, diabetic, and VAF347-treated diabetic mice two and eight months after diabetes was confirmed (n = 3/group per time point), CD4+ T cells were isolated by negative selection columns, and the levels of IL-17A in T cell lysates was quantified by ELISA analysis. This evidence concerns the gene IL17A and diabetes mellitus.